June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big Pharma Look Before It Leaps in Drug Discovery”. The report can be accessed here.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a Gaithersburg, Maryland-based AI company that is focused on the pharmaceutical R&D market. BullFrog uses AI to increase the success rate of drug development while reducing the time and investment it requires. The company commercializes a proprietary, end-to-end AI and ML platform that prepares biomedical data, identifies the biological drivers of disease, and supports development decisions. The platform targets a core inefficiency in drug development: bringing a new drug to market typically takes 10-15 years and $1-2 billion, and even then, roughly half of the drugs that reach Phase 3 still fail, often because developers picked the wrong target or could not identify which patients a drug actually helps.
Its core technology is a defensible competitive moat rooted in proprietary Johns Hopkins IP: an exclusive, worldwide license to three granted US patents covering the causal AI/ML engine, with protection running into 2037-2038. The technology was licensed from the Johns Hopkins University Applied Physics Laboratory (JHU-APL), where the underlying algorithms were first developed for defense work. Unlike many AI tools, the engine can explain how it reaches a conclusion rather than acting as a black box.
The product line is now complete and works end to end: bfPREP™ cleans and prepares messy research data in days instead of months, bfLEAP™ identifies the actual biological drivers of disease rather than mere correlations, and bfARENAS™, launched in March 2026, is a scenario-based decision engine that helps clients act on the findings, modeling different clinical, regulatory, and commercial paths so teams can evaluate the odds of success before committing time and money. The platform has already produced valuable discoveries, including work with Eleison Pharmaceuticals that identified a subgroup of patients in a Phase 3 pancreatic cancer trial associated with roughly a threefold improvement in survival, and discoveries of potential disease-driving genes and drug targets in MDD, schizophrenia, and bipolar disorder through a partnership with LIBD, for which BullFrog holds commercialization exclusivity. In March 2026, a first deal with a top five global drugmaker marked a turning point, applying bfLEAP™ to MDD, a market valued at more than $8 billion in 2025.
BullFrog trades at ~0.8x 2027E and ~0.3x 2028E EV/sales on our estimates, well below peer medians of ~26x and ~29x, respectively. The company has a meaningful addressable market opportunity in AI-driven drug discovery and peers executing on their commercial pipelines command significantly higher multiples.
About WTR. Modernizing Investor Engagement Through Research-Driven Strategies. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor engagement platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is open for everyone to access and distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.
